Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration

Whitepapers

Sponsored Content

How can real-time cell density monitoring improve Pichia pastoris fermentation? This application note explores the validation of Hamilton’s Dencytee Arc sensor during VHH (nanobody) production. Discover how phase-specific correlation models account for changing fermentation conditions, achieving strong agreement with off-line dry cell weight measurements and supporting more informed process control. Download the full application note to explore the validation approach and results.

Sponsored Content

How can real-time turbidity monitoring improve cell culture harvest clarification? This application note explores the use of Hamilton’s Dencytee Arc probe to continuously monitor centrate turbidity during the harvest of mAb-producing CHO cells. Discover how in-line measurements complement intermittent at-line testing, helping operators identify deviations and make timely, data-driven process adjustments. Download the full application note to explore the setup and measurement results.

Sponsored Content

A single compromised shipment can undo years of formulation work, trigger a regulatory hold or put patient safety at risk across the global supply chain. Selecting a current Good Manufacturing Practice (cGMP) compliant pharmaceutical packaging company means scrutinizing its compliance systems and protective design. Global sourcing reach, security features and impact on patient outcomes matter just as much as price and speed.

From next-generation biologics to smarter capsule technology and cleaner supplier communication, this ebook brings together 4 insights at where formulation science is headed and what it takes to get complex therapies safely from lab to patient. Inside, readers will find a look into the stability challenges of emerging biologics such as antibody-drug conjugates and bispecifics, including real-world case studies on taming viscosity and solubility at high concentrations. The industry's accelerating shift from IV to subcutaneous delivery is discussed, unpacking the regulatory approvals, patient-outcome data, and market forces turning at-home biologic dosing into standard practice. On the drug-delivery-innovation side, a feature on a novel capsule-in-capsule platform shows how liquid and solid actives can be combined in a single dose to cut pill burden without sacrificing performance. Rounding this eBook out, an IPEC-Americas explainer shows how the Excipient Information Package can replace slow, inconsistent supplier questionnaires with a standardized format that speeds qualification from months to days.

Sponsored Content

This executive summary examines how field-flow fractionation coupled with multi-angle light scattering (FFF-MALS) characterizes lipid nanoparticles (LNPs) as regulatory expectations from FDA, EMA, and USP converge on a shared set of critical quality attributes. It walks through how FFF-MALS resolves particle size, molar mass, and payload distribution in a single non-destructive run, and includes a case study comparing two authorized mRNA vaccines. Readers will see how size-resolved analysis uncovered differences in payload distribution that bulk-average methods missed.

Sponsored Content

In biologics development, a strong scientific idea is only the beginning. A molecule may show compelling biology in discovery, demonstrate good target engagement, and generate early excitement internally or with investors, but none of this guarantees that it can become a safe, manufacturable, and clinically viable therapeutic. That is the reality many early-stage companies face, and it is exactly why early development assessment matters. Early drug development is complex, multidisciplinary, and shaped by interdependent decisions. Data from discovery, drug substance, drug product, immunology, analytics, safety, and regulatory activities must ultimately come together in the first-in-human enabling package. Read this content piece to explore how at Lonza, these connected workstreams are assessed in a coordinated way, helping teams build a more complete and decision-ready foundation for development.

Sponsored Content

This custom eBook examines how advanced analytical characterization is changing biosimilar development following the FDA's October 2025 draft guidance. It covers modern SEC separations for biosimilar antibodies, LC-MS and MAM workflows for protein characterization and attribute monitoring, and the role of multi-angle light scattering (MALS) in biosimilar approval. A closing Q&A with Matthew A. Lauber, PhD, of Waters Corporation, explores how integrating these complementary techniques builds a more complete, regulatory-ready picture of biosimilarity.

This executive summary examines how FUJIFILM Biotechnologies' ShunzymeX™ platform addresses the purification challenges that make microbial expression systems slower and less predictable than monoclonal antibody workflows. Andrei Soliakov, PhD, a principal technical project lead of process development at FUJIFILM Biotechnologies, details the engineering of a scarless protease developed in partnership with the University of Edinburgh, along with proof-of-concept results across four structurally diverse model proteins. Readers will see how a standardized downstream workflow shortens the path from expression strain to GMP manufacturing.

Sponsored Content

Learn how key attributes such as encapsidation, aggregation, potency, purity, and genome integrity influence AAV quality and what analytical strategies are needed to characterize them with confidence.

Comprehensive characterization of biotherapeutics requires advanced analytical strategies capable of detecting and identifying low-abundant product quality attributes (PQAs), including post-translational modifications, aggregates, sequence variants, and conjugation sites. This eBook presents three technical articles demonstrating advanced LC-MS workflows that achieve up to 10X improvement in MS sensitivity for trace-level detection and confident identification of these challenging attributes.

This Quality and Regulations eBook, presented by PharmTech, PharmTech Europe, and BioPharm International® is your guide to quality and compliance strategy, covering everything from ICH Q5A(R2)'s viral safety expectations to what a real FDA warning letter reveals about AI's limits in GMP documentation. Industry leaders discuss how risk-based quality frameworks are accelerating biopharma development, alongside a look at how USP's digital standards are modernizing quality control labs without sacrificing rigor. This eBook offers a practical roadmap for building quality systems ready for 2026's regulatory landscape and beyond.

Learn how cloud-based historian platforms can simplify bioprocess data management by centralizing process data, improving collaboration, and enabling secure, browser-based access. This white paper explores key considerations for evaluating cloud-native solutions, including security, compliance, scalability, and how modern data management can help scientists and engineers gain greater value from their process data.

Discover how accurate oxygen transfer rate (OTR) characterization supports microbial fermentation for high-quality plasmid DNA production. This white paper demonstrates the sulfite depletion method for measuring OTR in the Distek BIOne 2L Single-Use Fermentor and explains why it provides a more representative approach than traditional methods for process development and scale-up.

Delivering clinical supplies into the European Union and United Kingdom requires rigorous oversight from a QP to ensure every batch meets regulatory, GMP, and trial-specific requirements. Yet, many sponsors face preventable delays, often due to incomplete documentation, limited supply chain visibility, or late communication of changes. This paper breaks down the core responsibilities of the QP, explains how European Union and United Kingdom expectations differ, and share practical steps sponsors can take to streamline the certification process. Readers will learn how to prepare audit-ready documentation, avoid common pitfalls that extend release timelines, and build efficient collaborations with QPs to keep studies moving without interruption.

Discover how scalable 3D suspension culture can improve human induced pluripotent stem cell (iPSC) expansion compared to traditional 2D methods. This poster demonstrates process development within a BIOne 2L single-use bioreactor, highlighting aggregate size control, cell viability, expansion performance, and cost efficiency while achieving a 60-fold expansion over five days using Defined Bioscience HiDef® S8™ medium.

Want to know what it really takes to protect a drug substance process's scientific integrity when it moves to a new manufacturing site? This executive summary, featuring the insights of Danielle Wittenwyler, PhD, Associate Director of Process Development, Drug Substance Lifecycle at Catalent, examines how late phase tech transfer can preserve process characterization (PC) as active scientific knowledge rather than static documentation. It outlines the common sources of transfer risk and describes a risk-based approach to bridging studies. The piece explains how preserved process knowledge supports more meaningful process validation (PV) and continued process verification (CPV) throughout the product lifecycle

BioPharm International speaks with David Cetlin, Cygnus Technologies, about MockV®, a non-infectious virus-like particle (VLP) technology designed to streamline viral clearance testing in biopharmaceutical manufacturing. Cetlin explains how the BSL-1 based approach allows companies to perform these assessments in-house, replacing reliance on costly, CRO-run live viral spiking studies with easy-to-use. The conversation also covers data comparability to the XMuLV gold standard, regulatory traction, and which internal teams are best positioned to lead adoption.

Meet the soloLAB containment isolator. Perfect for providing operator protection from hazardous materials or creating inert gas environments at laboratory scale. With its instant “pop up”deployment the soloLAB is ready for use in minutes.

ILC Dover’s custom plastic solutions are engineered for pharmaceutical, biopharma, and medical environments. Manufactured from hygienic, medical- and pharmagrade polymer that meets USP Class VI and FDA standards, with smooth, non-porous surfaces designed for easy cleaning and cleanroom compliance.